As part of the Planet Microcap Showcase, Emyria CEO Dr Michael Winlo gave an overview of the company’s progress to date, as well as an exciting glimpse into what the future holds for Emyria’s programs tackling unmet needs in neuroscience and mental health.

“We want to register multiple cannabinoid-based treatments for multiple indications around the world and leverage our real-world data to guide that development. We also want to be a global leader in the development of next-generation neuropsychiatric treatments inspired by MDMA,” he said.

Watch the full webinar here: Emyria Limited (ASX: EMD) Webcast | Planet MicroCap Showcase: VIRTUAL 2022 – YouTube